PRINCETON, N.J. & NEW YORK, Jun 27, 2014 (BUSINESS WIRE) -- Bristol-Myers Squibb Company BMY -0.74% and Pfizer Inc. PFE -0.14% today announced that the Committee for Medicinal Products for Human Use ...

Results highlighted in two oral presentations at the American Society of Hematology Annual Meeting In a second oral presentation, results from a sub-group analysis of the primary study were ...

Eliquis® (apixaban) Demonstrated Comparable Efficacy and Significantly Lower Rates of Major Bleeding in Patients Compared to Current Standard of Care for the Treatment of Acute Venous Thromboembolism ...

In contrast, no added benefit proven in initial treatment of patients with BMI up to 28 kg/m2 and in long-term prevention Institute for Quality and Efficiency in Health Care Apixaban (trade name ...

Bristol-Myers Squibb and Pfizer announced that the FDA has accepted for review a supplemental New Drug Application (sNDA) for Eliquis (apixaban), for prophylaxis of deep vein thrombosis (DVT), which ...

Thromboembol in blood vessel. Clot formation, 3D illustration Researchers sought to compare oral apixaban and subcutaneous dalteparin for treating patients with cancer-related venous thromboembolism.

ASH: Extended apixaban cuts recurrent VTE risk Taking apixaban for an additional year after standard treatment reduced recurrent venous thromboembolism without increasing major bleeding. HealthDay ...

LAS VEGAS, NV—The first day of VIVA 2017 began with some timely insights into pharmacotherapy with non-vitamin K oral anticoagulants (NOACs) in patients with deep vein thrombosis (DVT), and a look ...

The disadvantages of dabigatran include a higher cost compared with warfarin, the need for twice-daily dosing, and a slightly increased risk for gastrointestinal bleeding (6.1% with dabigatran vs 4% ...

Please provide your email address to receive an email when new articles are posted on . Treatment of venous thromboembolism with oral apixaban was noninferior to subcutaneous dalteparin, without ...

In patients with active cancer who have been hospitalized for a venous thromboembolism (VTE) event, rivaroxaban (Xarelto; Bayer/Janssen) is as effective as apixaban (Eliquis; Bristol-Myers Squibb) in ...

PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)--The Bristol-Myers Squibb-Pfizer Alliance today announced results from retrospective real-world data analyses reporting outcomes on the safety and ...